Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
JF Gainor, AT Shaw - Journal of clinical oncology, 2013 - ascopubs.org
… of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung cancer (…
emphasis on understanding the molecular characteristics of tumor specimens. It is now recognized …
emphasis on understanding the molecular characteristics of tumor specimens. It is now recognized …
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story
LV Sequist, TJ Lynch - Annu. Rev. Med., 2008 - annualreviews.org
… the treatment of non–small cell lung cancer (NSCLC). The use of … development of EGFR
tyrosine kinase inhibitors, the discovery … of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …
tyrosine kinase inhibitors, the discovery … of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …
Tyrosine kinase inhibitors (TKIs) in lung cancer treatment: a comprehensive analysis
S Murugesan, J Murugesan… - Current cancer drug …, 2021 - ingentaconnect.com
… the kinase inhibitors. However, many gaps remain in understanding the mechanisms of kinase
inhibitors … and non-receptor tyrosine kinase inhibitors and their novel role in lung cancer. …
inhibitors … and non-receptor tyrosine kinase inhibitors and their novel role in lung cancer. …
Role of tyrosine kinase inhibitors in lung cancer
… tyrosine kinase controlled pathways. Epidermal growth factor receptor tyrosine kinase
inhibitors … in patients with refractory non-small cell lung cancer (NSCLC). Early studies with …
inhibitors … in patients with refractory non-small cell lung cancer (NSCLC). Early studies with …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
GW Krystal, S Honsawek, J Litz, E Buchdunger - Clinical Cancer Research, 2000 - AACR
… cell lung cancers express the Kit receptor tyrosine kinase … , suggesting that inhibitors of Kit
tyrosine kinase activity could … was designed as an Abl tyrosine kinase inhibitor, but also has …
tyrosine kinase activity could … was designed as an Abl tyrosine kinase inhibitor, but also has …
[HTML][HTML] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
GJ Riely - Journal of Thoracic Oncology, 2008 - Elsevier
… Approximately 10 to 15% of patients with non-small cell lung cancer have tumors that … to
treatment with the first-generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib. A …
treatment with the first-generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib. A …
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
JA Engelman, PA Jänne - Clinical Cancer Research, 2008 - AACR
… tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non–small cell lung
cancer … for these cancers. Studies over the last few years have identified two different EGFR …
cancer … for these cancers. Studies over the last few years have identified two different EGFR …
Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer
… non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative
example of the successes in targeting oncogene addiction in cancer and the role of tumor-specific …
example of the successes in targeting oncogene addiction in cancer and the role of tumor-specific …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
PS Hammerman, PA Jänne, BE Johnson - Clinical cancer research, 2009 - AACR
… Although the PI3K is undoubtedly important in lung cancers, no specific mutations in … lung
tumors to date (61). We would anticipate further development of PI3K inhibitors in lung cancer …
tumors to date (61). We would anticipate further development of PI3K inhibitors in lung cancer …
相关搜索
- cell lung cancer tyrosine kinase inhibitors
- growth factor receptor tyrosine kinase inhibitors
- egfr tyrosine kinase inhibitors
- tyrosine kinase inhibitor sti571
- receptor tyrosine kinase inhibitors lung cancers
- lung cancer treatment tyrosine kinase inhibitors
- role of tyrosine kinase inhibitors
- first line tyrosine kinase inhibitors
- other tyrosine kinase inhibitors lung cancer
- acquired resistance mechanisms tyrosine kinase inhibitors
- development of resistance tyrosine kinase inhibitors
- multi-targeted tyrosine kinase inhibitors
- individualized therapy tyrosine kinase inhibitors
- network meta analysis tyrosine kinase inhibitors
- efficacy and resistance tyrosine kinase inhibitors
- comprehensive analysis tyrosine kinase inhibitors